HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Seizure in Florida, FDA Targets Kratom As Unsafe For Any Use

Executive Summary

Kratom industry says complaint filed in Florida federal court shows FDA’s switching reasons to stop all sales of the ingredient in the US.

You may also be interested in...



Kratom Industry Group Has First Qualifier For Its GMP Standards Exceeding FDA's

Online retailer and supplement brand Kraken Kratom is first business American Kratom Association recognized with its GMP Qualified Vendor status. But, FDA reiterates kratom should not be used in supplements until an NDI notification is submitted showing a reasonable expectation of safety for its intended use, and DEA still has pending a proposed order to schedule kratom constituent ingredients as controlled substances.

FDA Turns Kratom's Future In US Dietary Supplement Market Into History

FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."

Progress On Adding OTC Drugs To US Market? Room To Move But Label Format Limits Options

Changes for supporting OTC labeling for drugs currently available Rx-only and indicated for chronic, more complicated conditions, aren’t minor and won’t happen within limits of one-dimensional text media printed on OTC drug containers, packages and inserts.

Topics

UsernamePublicRestriction

Register

RS151362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel